Opinion & Analysis
Physician perspectives, editorial analysis, and expert commentary on the future of GLP-1 therapy and the standard of care.
Opinion
A Prescription Is Not a Protocol: Why the GLP-1 Standard of Care Must Change
The WHO classified obesity as a chronic disease requiring long-term pharmacotherapy. A 5-minute video call doesn't meet that standard.
Editorial
The Compounding Loophole Is Closed. Now What?
The regulatory foundation that built a multi-billion-dollar compounding market has evaporated. Patients deserve a clear transition plan.
Analysis
Oral vs. Injectable: Why Convenience May Matter More Than Efficacy for Population Health
7–9% weight loss sounds modest next to 20%. But if oral GLP-1s double the eligible population, the public health math changes dramatically.
Opinion
The SELECT Trial Changed How Physicians Think About Obesity. It Should Change How You Think Too.
A 20% reduction in heart attacks and strokes. This is no longer about aesthetics. This is cardiology.
Physician-Led Program · Lion MD
Compounded Tirzepatide
Dual-action GLP-1/GIP. Enhanced appetite control + metabolic improvement.
From $139/mo
Get Started →